Previous close | 7.60 |
Open | 7.60 |
Bid | 7.35 x 0 |
Ask | 7.90 x 0 |
Day's range | 7.60 - 7.60 |
52-week range | 6.15 - 13.80 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -14.29% and 0.39%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
To get a sense of who is truly in control of Evolus, Inc. ( NASDAQ:EOLS ), it is important to understand the ownership...
Shares of Evolus (NASDAQ: EOLS) were up by 27.1% for the week as of Friday afternoon, according to data provided by S&P Global Market Intelligence. The medical aesthetics company specializes in using neurotoxins as aesthetic therapies. The company said in its announcement that it expected fourth-quarter revenue of $43.6 million, up 26% year over year, and full-year revenue of $148.6 million, up 49% over 2021.